Literature DB >> 2339458

Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets.

S Chemtob1, K Beharry, J Rex, D R Varma, J V Aranda.   

Abstract

To assess whether prostanoids have a role in setting the blood pressure limits of cerebral blood flow autoregulation in newborn animals, we measured cerebral blood flow and prostanoid concentrations in blood from the sagittal sinus over a wide range of mean systemic blood pressures (17-117 mm Hg) in eight newborn piglets treated with 30 mg/kg i.v. ibuprofen and in eight vehicle-treated piglets. Blood pressure was adjusted by inflating balloon-tipped catheters placed at the aortic isthmus and root to induce hypertension and hypotension, respectively, 80 minutes apart in each piglet. Cerebral blood flow and concentrations of prostaglandins E and F2 alpha, 6-keto-prostaglandin F1 alpha, and thromboxane B2 in blood from the sagittal sinus and left subclavian artery were measured 20 minutes before (baseline) and during each blood pressure adjustment. In vehicle-treated piglets, cerebral blood flow was constant at blood pressures between 50 and 90 mm Hg (r = 0.06, p = 0.85). When blood pressure was reduced to less than 50 mm Hg, thromboxane B2 concentration in the sagittal sinus increased by 597 +/- 42% and concentrations of the prostaglandins increased by an average of 308 +/- 45% (p less than 0.05). When blood pressure was raised to greater than 90 mm Hg, concentrations of the prostaglandins increased by an average of 46 +/- 11%, with no change in the concentration of thromboxane B2. Treatment with ibuprofen reduced the baseline concentrations of all prostanoids and prevented their changing during hypotension and hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339458     DOI: 10.1161/01.str.21.5.777

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  19 in total

1.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2019-06-21

Review 2.  Therapeutic potential to reduce brain injury in growth restricted newborns.

Authors:  Julie A Wixey; Kirat K Chand; Lily Pham; Paul B Colditz; S Tracey Bjorkman
Journal:  J Physiol       Date:  2018-05-23       Impact factor: 5.182

3.  Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.

Authors:  Arne Ohlsson; Sachin S Shah
Journal:  Cochrane Database Syst Rev       Date:  2020-01-27

4.  Treatment of patent ductus arteriosus with ibuprofen.

Authors:  B Van Overmeire; I Follens; S Hartmann; W L Creten; K J Van Acker
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-05       Impact factor: 5.747

5.  Common clinical and practical questions on the use of intravenous Ibuprofen lysine for the treatment of patent ductus arteriosus.

Authors:  Bart Van Overmeire
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

6.  Prostaglandin FP receptor inhibitor reduces ischemic brain damage and neurotoxicity.

Authors:  Yun Tai Kim; Sang Kwan Moon; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurobiol Dis       Date:  2012-06-16       Impact factor: 5.996

7.  Premature babies and pharmacology.

Authors:  J Hamilton
Journal:  CMAJ       Date:  1995-12-15       Impact factor: 8.262

8.  Ontogenic increase in PGE2 and PGF2 alpha receptor density in brain microvessels of pigs.

Authors:  D Y Li; D R Varma; S Chemtob
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

9.  PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia.

Authors:  Sofiyan Saleem; Abdullah Shafique Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurotox Res       Date:  2009-02-11       Impact factor: 3.911

10.  Effect of oral ibuprofen on patent ductus arteriosus in premature newborns.

Authors:  Sabry Ghanem; Mansour Mostafa; Mohamed Shafee
Journal:  J Saudi Heart Assoc       Date:  2010-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.